Plain-English translation of NCT07708142 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new eye implant called to treat a condition called retinal vein occlusive macular edema — swelling in the back of the eye caused by a blocked blood vessel. Researchers want to see if works as well as, or better than, the current standard treatment, which uses the same type of implant. You would be randomly assigned to receive either the new treatment or the standard treatment and followed for 6 months.
Swelling in the retina from blocked blood vessels can cause blurred vision and vision loss. While treatments exist, doctors want to find better options that work more effectively and safely for patients with this condition.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have an antibiotic eye drop applied before receiving an injection of the eye implant into your eye. You will then visit the clinic for follow-up appointments over 6 months so doctors can check how well the treatment is working and monitor for any side effects. Half of the participants will receive the new implant, and half will receive the standard treatment — you won't know which one you're getting.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
South Korea